Obesity and OverweightObesity PCTNCT06859697
The Efficacy and Safety of Herbal Medicine Treatment for Obese Patients With Spinal and Joint Pain
A study testing Herbal medicine treatment and Life Guidance in people with Obesity and Overweight, run by Jaseng Medical Foundation at 1 site in South Korea.
Trial summary
This study is a pragmatic pilot randomized controlled trial aimed at investigating the effectiveness of herbal medicine treatment for obese patients with spinal and joint pain, using a control group receiving lifestyle guidance. Read more about this study
- Who is it for?
- Ages 19 to 69 years
- Conditions the study is for
- Obesity and Overweight
- What is being tested?
- Herbal medicine treatment and Life Guidance
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteSouth Korea
- Study dates
- 30 Apr 2025to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 69 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged 19 years or older but under 70 years.
- Individuals with a BMI of 25 kg/m² or higher, meeting the Asia-Pacific obesity criteria.
- Individuals experiencing spinal or joint pain, with the most severe pain rated as NRS 5 or higher.
- Individuals who voluntarily agree to participate in the clinical trial and sign the consent form.
Who cannot join
- Presence of findings on X-ray examination of the pain site, such as acute fractures or dislocations, requiring surgical intervention.
- Diagnosis of specific diseases that may cause secondary obesity (e.g., Cushing's syndrome, hypothyroidism, insulinoma, adult growth hormone deficiency, etc.).
- Current use of medications related to obesity treatment or a history of taking such medications within the past month.
- Presence of other chronic diseases that may interfere with treatment efficacy or interpretation of results, such as stroke, myocardial infarction, kidney disease, active hepatitis, diabetic neuropathy, dementia, epilepsy, etc.
- Current use of steroids, immunosuppressants, psychiatric medications, or other drugs that may affect study outcomes.
- Unsuitability or safety concerns for herbal medicine treatment: individuals with conditions or post-surgical complications affecting drug absorption or digestion, severe liver disease, or kidney disease.
Show all 10Show fewer
- Pregnant or planning to become pregnant, or currently breastfeeding.
- Participation in other clinical trials, except for observational studies without therapeutic intervention.
- Difficulty in providing informed consent.
- Other cases where the investigator deems participation in the clinical study inappropriate.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site
Jaseng Hospital of Korean Medicine
Seoul, Gangnam-Gu, 135-896
About this study
Official title: The Efficacy and Safety of Herbal Medicine Treatment for Obese Patients With Spinal and Joint Pain: A Pragmatic Randomized Controlled Pilot Clinical Trial
This study is a pragmatic pilot randomized controlled trial aimed at investigating the effectiveness of herbal medicine treatment for obese patients with spinal and joint pain, using a control group receiving lifestyle guidance.
Read the detailed description
- Background Obesity has been defined as a chronic disease requiring long-term treatment by the World Health Organization (WHO). Additionally, an increase in body fat is associated with a higher prevalence of musculoskeletal pain and related disorders. Therefore, this study aims to evaluate the efficacy of herbal medicine treatment by investigating whether a reduction in obesity affects spinal and joint pain in obese patients, who constitute a significant proportion of patients visiting Korean medicine clinics and hospitals for spinal and joint pain.
- Patient Recruitment and Screening Phase
- Patient Recruitment Forty patients meeting the inclusion/exclusion criteria will be recruited starting from the date of IRB registration. Researchers will use block randomization to allocate participants. After obtaining written consent from patients who meet the criteria, they will be assigned to the study. The probability of assignment to each group will be 1:1.
- Allocation Concealment and Blinding Since blinding is not feasible for this study, it will be conducted as an open-label clinical trial. However, assessor blinding will be implemented. The evaluator, who will not participate in the intervention and will be blinded to group allocation, will conduct assessments in a separate space before the intervention. This role will be performed by a research nurse or a specialist in training.
- Treatment and Evaluation Phase
- Control and Experimental Groups The experimental group will receive herbal medicine treatment in addition to standard care, while the control group will receive lifestyle guidance only. Both groups will be provided with identical educational materials and guidance on lifestyle modifications aimed at weight loss. The educational materials will include information on the definition and causes of obesity, as well as explanations on weight reduction and lifestyle management applicable to various situations, including diet and exercise. Lifestyle guidance will be based on the provided materials. During the first visit, participants will receive comprehensive education on the study materials. Follow-up education sessions will be conducted every two weeks for a total of six weeks, during which changes in participants' symptoms will also be evaluated. Both groups will receive lifestyle education under identical conditions to evaluate the additional effects of herbal medicine treatment.
- Study Duration and Observation Points The total participation period for each subject will be 12 weeks, including a 6-week treatment period and a 6-week follow-up period. Baseline data will be collected at the time of study enrollment (Week 0), and the primary endpoint will be at Week 6. Data will be collected during visits at Week 0, Week 2, and Week 4 during the treatment period, as well as during follow-up visits at Week 6 (primary endpoint), Week 8, and Week 12.
- Data Collection for Evaluation i. Primary Outcome The primary outcome will be the BMI at Week 6, after the completion of the treatment intervention. ii. Secondary Outcomes
Secondary outcomes will be assessed at Week 0, Week 2, Week 4, Week 6 (primary endpoint), Week 8, and Week 12. The following indicators will be evaluated:
Body fat percentage Body fat mass Skeletal muscle mass Body weight Visceral fat level Quality of life (EQ-5D-5L) IWQOL-Lite (Impact of Weight on Quality of Life - Lite) The most painful area in the spinal and joint regions NRS (Numeric Rating Scale) for pain intensity Adherence to the intervention Adverse effects
- Follow-Up Phase After the 6-week intervention period, a 6-week follow-up will be conducted to assess changes in the participants' symptoms.
At Weeks 6, 8, and 12, evaluations will be conducted using the same parameters as during the treatment visits, including the primary outcome (BMI) and secondary outcomes (body weight, body fat percentage, body fat mass, skeletal muscle mass, EQ-5D, IWQOL-Lite, the most painful spinal/joint area, pain intensity at that site, adherence, and adverse effects). The time window for follow-up evaluations will be ±5 days for Week 6 and ±7 days for Weeks 8 and 12.
Blood tests will be conducted at Week 6, aligned with the start of herbal medicine treatment. The blood test parameters will be the same as those performed during the screening phase.
- Monitoring
Although this is a researcher-initiated clinical study, monitoring will be conducted by a third party in accordance with the institution's HRPP (Human Research Protection Program) policy and KCGP (Korean Good Clinical Practice) guidelines. The purpose of monitoring is to ensure that the following are maintained throughout the study period and to prevent recurrence of any non-compliance through proper reporting procedures:
Monitoring intervals will be appropriately spaced, and the frequency will depend on the rate of participant enrollment and the data collected.
- Conditions
- Obesity and Overweight
- Being tested
- Herbal medicine treatment, Life Guidance
- Keywords
- Obesity Herbal Medicine
- Medical subject headings
- Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Herbal medicine treatmentProcedure or surgery
Herbal medicine treatment is a treatment using complex extract of medicinal herbs prescribed by a Korean medicine doctor who has completed specialized education to diagnose the health condition and symptoms of patients
Life GuidanceProcedure or surgery
Educational materials will be distributed, and education on daily life management for weight loss will be conducted. The educational materials consist of information on the definition and causes of obesity, explanations on weight reduction and daily life management applicable to various situations such as exercise and diet, and the effects of these practices.
| Study group | Role | What they receive |
|---|---|---|
| Herbal Medicine Group | Experimental | Participants in the herbal medicine treatment group will visit the clinic every 14 days for prescription and follow-up observations. Herbal medicine will be prescribed in 14-day doses, and participants will orally take a total of 42 days' worth of herbal medicine during the treatment period.
This study is a pragmatic clinical trial, and there are no restrictions on the types of herbal medicine used. Prescriptions will be made at the discretion of the medical staff, with the primary goal of improving obesity.
All prescriptions will be made by Korean medicine doctors with at least five years of clinical experience.
After the prescription is issued, the herbal medicine will be delivered to participants via courier for consumption. Participants will be instructed to store all herbal medicine in a refrigerator.
Compliance with herbal medicine consumption will be confirmed by counting the remaining doses during participants' visits and recording the results. Receives: Procedure: Herbal medicine treatment |
| Life Guidance Group | Active comparator | Educational materials will be distributed, and education sessions will be conducted. Receives: Procedure: Life Guidance |
What is being measured
The primary outcome is the main question the study is designed to answer.
BMI(Body Mass Index)
Body weight (kg) divided by the square of height (m) is used as a diagnostic criterion for obesity. Based on the significant increase in obesity-related diseases associated with body mass index (BMI), the Asia-Pacific region and the Korean Society for the Study of Obesity have established the criteria as follows: a BMI of 23 kg/m² or higher is classified as overweight or pre-obesity, and a BMI of 25 kg/m² or higher is classified as obesity.
Measured: Change from baseline to Week 6
Secondary outcomes (10)
Body Fat Percentage
Body fat percentage (percent body fat, PBF, %fat) is the proportion of body fat relative to total body weight. Obesity classification based on body fat percentage is as follows: for men, less than 10.0% is classified as underweight, 10.0-20.0% as normal, 20.0-25.0% as overweight, and 25.0% or higher as obesity; for women, less than 18.0% is classified as underweight, 18.0-28.0% as normal, 28.0-33.0% as overweight, and 33.0% or higher as obesity.
Measured: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
Body fat mass
Body fat mass refers to the absolute amount of fat in the body, measured in kilograms (kg). It represents the total weight of fat tissue in the body and is an important indicator for assessing obesity and overall body composition. Unlike body fat percentage, which is a relative measure, body fat mass provides an absolute value, making it useful for tracking changes in fat levels over time, especially during weight management or fitness programs.
Measured: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
Skeletal Muscle Mass
Skeletal muscle mass refers to the total weight of skeletal muscles in the body, typically measured in kilograms (kg). Skeletal muscles are responsible for voluntary movements and play a crucial role in physical activity, metabolism, and overall health. This measurement is used to assess muscle development and monitor changes due to exercise, aging, or medical conditions
Measured: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
Body weight
Body weight refers to the total mass of an individual's body, typically measured in kilograms (kg) or pounds (lbs). It includes the combined weight of bones, muscles, fat, organs, fluids, and other tissues. Body weight is a fundamental parameter for assessing overall health and is often used in conjunction with other measurements, such as body fat percentage, skeletal muscle mass, and BMI, to evaluate physical fitness, nutritional status, and the risk of developing obesity-related diseases.
Measured: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
Visceral fat level
Visceral fat level refers to the amount of fat stored around internal organs in the abdominal cavity, such as the liver, pancreas, and intestines. In InBody devices, visceral fat level is expressed on a scale ranging from 1 to 20, where a level below 10 is generally considered healthy, while a level of 10 or higher indicates excessive visceral fat that may require management.
Measured: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
5-Level EuroQol-5 Dimension (EQ-5D-5L)
The 5-Level EuroQol-5 Dimension (EQ-5D-5L) is one of the most widely used indirect measurement methods for calculating the quality weight of a specific health state. It evaluates health status from multiple perspectives and utilizes pre-assigned preference scores for each functional level to indirectly calculate the quality weight of a particular health condition. The EQ-5D-5L consists of five items, each addressing the degree of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item is assigned a specific weight based on its level, and a preference score calculation formula is provided using these weights and constants.
Measured: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
IWQOL-Lite (Impact of Weight on Quality of Life - Lite)
The IWQOL-Lite is a questionnaire tool developed to assess the impact of weight on quality of life and is primarily used in obesity research and evaluating the effectiveness of weight loss treatments. It is a simplified version of the IWQOL (Impact of Weight on Quality of Life) and consists of 31 items. The questionnaire is divided into five subscales: physical function, self-esteem, sexual life, interpersonal stress, and work-related activities.
Measured: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
Areas of Spinal and Joint Pain
To investigate the primary pain areas in the spinal and joint regions of obese patients, the severity of pain in the single most painful area is assessed.
Measured: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
NRS (Numeric Rating Scale)
The Numeric Rating Scale (NRS) is used to assess the severity of pain in the single most painful area. Patients rate their pain on a scale from 0 to 10, where 0 represents "no pain at all" and 10 represents "the worst pain imaginable or unbearable pain." This scale provides a simple and effective way to quantify pain levels for clinical evaluation and treatment planning.
Measured: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
Adherence
To evaluate treatment adherence, for participants in the herbal medicine treatment group, the total number of prescribed herbal medicine packs and the number of consumed packs are assessed from Week 0 to Week 6 and recorded in the Case Report Form (CRF).
Additionally, for all participants, the number of days they adhered to dietary and exercise regimens is also investigated and documented in the CRF. This comprehensive adherence evaluation helps ensure accurate monitoring of participants' compliance with treatment protocols and lifestyle modifications.
Measured: Week 2, Week 4, Week 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2025
- Study start30 Apr 2025
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity and OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jaseng Medical Foundation
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- In-Hyuk Ha, PhD, Principal investigator, Jaseng Medical Foundation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06859697
- Sponsor's protocol ID
- JS-CT-2025-03
- Other IDs
- Jaseng Medical Foundation
- Acronym
- Obesity PCT
- Status last verified
- Jul 2026
- First submitted
- 26 Feb 2025
- Last updated
- 2 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Efficacy and Safety of Herbal Medicine Treatment for Obese Patients With Spinal and Joint Pain: A Pragmatic Randomized Controlled Pilot Clinical Trial
- ClinicalTrials.gov ID
- NCT06859697
- Acronym / sponsor ID
- Obesity PCT / JS-CT-2025-03
- Conditions
- Obesity and Overweight
- Keywords
- Obesity Herbal Medicine
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Jaseng Medical FoundationUniversity, hospital or other
- Study start
- 30 Apr 2025 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 5 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a pragmatic pilot randomized controlled trial aimed at investigating the effectiveness of herbal medicine treatment for obese patients with spinal and joint pain, using a control group receiving lifestyle guidance.
Detailed description
- Background Obesity has been defined as a chronic disease requiring long-term treatment by the World Health Organization (WHO). Additionally, an increase in body fat is associated with a higher prevalence of musculoskeletal pain and related disorders. Therefore, this study aims to evaluate the efficacy of herbal medicine treatment by investigating whether a reduction in obesity affects spinal and joint pain in obese patients, who constitute a significant proportion of patients visiting Korean medicine clinics and hospitals for spinal and joint pain.
- Patient Recruitment and Screening Phase
- Patient Recruitment Forty patients meeting the inclusion/exclusion criteria will be recruited starting from the date of IRB registration. Researchers will use block randomization to allocate participants. After obtaining written consent from patients who meet the criteria, they will be assigned to the study. The probability of assignment to each group will be 1:1.
- Allocation Concealment and Blinding Since blinding is not feasible for this study, it will be conducted as an open-label clinical trial. However, assessor blinding will be implemented. The evaluator, who will not participate in the intervention and will be blinded to group allocation, will conduct assessments in a separate space before the intervention. This role will be performed by a research nurse or a specialist in training.
- Treatment and Evaluation Phase
- Control and Experimental Groups The experimental group will receive herbal medicine treatment in addition to standard care, while the control group will receive lifestyle guidance only. Both groups will be provided with identical educational materials and guidance on lifestyle modifications aimed at weight loss. The educational materials will include information on the definition and causes of obesity, as well as explanations on weight reduction and lifestyle management applicable to various situations, including diet and exercise. Lifestyle guidance will be based on the provided materials. During the first visit, participants will receive comprehensive education on the study materials. Follow-up education sessions will be conducted every two weeks for a total of six weeks, during which changes in participants' symptoms will also be evaluated. Both groups will receive lifestyle education under identical conditions to evaluate the additional effects of herbal medicine treatment.
- Study Duration and Observation Points The total participation period for each subject will be 12 weeks, including a 6-week treatment period and a 6-week follow-up period. Baseline data will be collected at the time of study enrollment (Week 0), and the primary endpoint will be at Week 6. Data will be collected during visits at Week 0, Week 2, and Week 4 during the treatment period, as well as during follow-up visits at Week 6 (primary endpoint), Week 8, and Week 12.
- Data Collection for Evaluation i. Primary Outcome The primary outcome will be the BMI at Week 6, after the completion of the treatment intervention. ii. Secondary Outcomes
Secondary outcomes will be assessed at Week 0, Week 2, Week 4, Week 6 (primary endpoint), Week 8, and Week 12. The following indicators will be evaluated:
Body fat percentage Body fat mass Skeletal muscle mass Body weight Visceral fat level Quality of life (EQ-5D-5L) IWQOL-Lite (Impact of Weight on Quality of Life - Lite) The most painful area in the spinal and joint regions NRS (Numeric Rating Scale) for pain intensity Adherence to the intervention Adverse effects
- Follow-Up Phase After the 6-week intervention period, a 6-week follow-up will be conducted to assess changes in the participants' symptoms.
At Weeks 6, 8, and 12, evaluations will be conducted using the same parameters as during the treatment visits, including the primary outcome (BMI) and secondary outcomes (body weight, body fat percentage, body fat mass, skeletal muscle mass, EQ-5D, IWQOL-Lite, the most painful spinal/joint area, pain intensity at that site, adherence, and adverse effects). The time window for follow-up evaluations will be ±5 days for Week 6 and ±7 days for Weeks 8 and 12.
Blood tests will be conducted at Week 6, aligned with the start of herbal medicine treatment. The blood test parameters will be the same as those performed during the screening phase.
- Monitoring
Although this is a researcher-initiated clinical study, monitoring will be conducted by a third party in accordance with the institution's HRPP (Human Research Protection Program) policy and KCGP (Korean Good Clinical Practice) guidelines. The purpose of monitoring is to ensure that the following are maintained throughout the study period and to prevent recurrence of any non-compliance through proper reporting procedures:
Monitoring intervals will be appropriately spaced, and the frequency will depend on the rate of participant enrollment and the data collected.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Herbal Medicine Group | Experimental | Procedure: Herbal medicine treatmentParticipants in the herbal medicine treatment group will visit the clinic every 14 days for prescription and follow-up observations. Herbal medicine will be prescribed in 14-day doses, and participants will orally take a total of 42 days' worth of herbal medicine during the treatment period. This study is a pragmatic clinical trial, and there are no restrictions on the types of herbal medicine used. Prescriptions will be made at the discretion of the medical staff, with the primary goal of improving obesity. All prescriptions will be made by Korean medicine doctors with at least five years of clinical experience. After the prescription is issued, the herbal medicine will be delivered to participants via courier for consumption. Participants will be instructed to store all herbal medicine in a refrigerator. Compliance with herbal medicine consumption will be confirmed by counting the remaining doses during participants' visits and recording the results. |
| Life Guidance Group | Active comparator | Procedure: Life GuidanceEducational materials will be distributed, and education sessions will be conducted. |
Who may qualify
- Ages
- 19 to 69 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients aged 19 years or older but under 70 years.
- Individuals with a BMI of 25 kg/m² or higher, meeting the Asia-Pacific obesity criteria.
- Individuals experiencing spinal or joint pain, with the most severe pain rated as NRS 5 or higher.
- Individuals who voluntarily agree to participate in the clinical trial and sign the consent form.
Key exclusion criteria (10 listed)
- Presence of findings on X-ray examination of the pain site, such as acute fractures or dislocations, requiring surgical intervention.
- Diagnosis of specific diseases that may cause secondary obesity (e.g., Cushing's syndrome, hypothyroidism, insulinoma, adult growth hormone deficiency, etc.).
- Current use of medications related to obesity treatment or a history of taking such medications within the past month.
- Presence of other chronic diseases that may interfere with treatment efficacy or interpretation of results, such as stroke, myocardial infarction, kidney disease, active hepatitis, diabetic neuropathy, dementia, epilepsy, etc.
- Current use of steroids, immunosuppressants, psychiatric medications, or other drugs that may affect study outcomes.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Herbal medicine treatmentHerbal medicine treatment is a treatment using complex extract of medicinal herbs prescribed by a Korean medicine doctor who has completed specialized education to diagnose the health condition and symptoms of patients | Procedure or surgery | Herbal Medicine Group |
| Life GuidanceEducational materials will be distributed, and education on daily life management for weight loss will be conducted. The educational materials consist of information on the definition and causes of obesity, explanations on weight reduction and daily life management applicable to various situations such as exercise and diet, and the effects of these practices. | Procedure or surgery | Life Guidance Group |
Primary outcome
BMI(Body Mass Index)
Time frame: Change from baseline to Week 6
Body weight (kg) divided by the square of height (m) is used as a diagnostic criterion for obesity. Based on the significant increase in obesity-related diseases associated with body mass index (BMI), the Asia-Pacific region and the Korean Society for the Study of Obesity have established the criteria as follows: a BMI of 23 kg/m² or higher is classified as overweight or pre-obesity, and a BMI of 25 kg/m² or higher is classified as obesity.
10 secondary outcomes
Body Fat Percentage
Time frame: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
Body fat mass
Time frame: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
Skeletal Muscle Mass
Time frame: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
Body weight
Time frame: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
Visceral fat level
Time frame: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
5-Level EuroQol-5 Dimension (EQ-5D-5L)
Time frame: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
IWQOL-Lite (Impact of Weight on Quality of Life - Lite)
Time frame: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
Areas of Spinal and Joint Pain
Time frame: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
NRS (Numeric Rating Scale)
Time frame: Baseline(Week 0), Week 2, Week 4, Week 6, Week 8, Week 12
Adherence
Time frame: Week 2, Week 4, Week 6
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Obesity and Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
In-Hyuk Ha, PhD principal investigator
Jaseng Medical Foundation
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Herbal medicine treatment and Life Guidance in people with Obesity and Overweight, run by Jaseng Medical Foundation at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
BMI(Body Mass Index) (time frame: Change from baseline to Week 6). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.